SK pharmteco, a global CDMO for small molecules and advanced therapies, and AaviGen GmbH, a preclinical stage biotechnology company focused curative gene therapies for cardiovascular and cardiopulmonary diseases, entered a multi-year manufacturing agreement wherein SK pharmteco will be the preferred manufacturing partner for Aavigen’s lead gene therapy product AVG-101 for the treatment of heart failure. 
 
AaviGen’s heart-specific adeno-associated viral vector technology enables the development of therapies that target and reverse the underlying molecular causes of heart muscle dysfunction. By focusing on key areas such as cardioprotection, contractility, and energy metabolism, AaviGen aims to improve patient outcomes and restoring normal cardiac function. 
 
“SK pharmteco is a key partner for AaviGen as part of our strategy to develop and commercialize innovative gene therapies against diseases of the cardiovascular and cardiovascular system,” said Patrick Most, CEO of AaviGen. “The SK pharmteco team offered the trust, competence, and understanding of how a young company like AaviGen must operate in a dynamic market from the first minute of our interactions. We look forward to the collaboration with great confidence.” 
  
“We are thrilled to partner with AaviGen on their innovative gene therapy for heart failure,” said Patrick Mahieux, SK pharmteco’s President of Cell and Gene, Europe. “Our deep expertise in viral vector manufacturing and our commitment to quality and efficiency make us the ideal partner to support the development and commercialization of this promising therapy. We look forward to contributing to the advancement of this groundbreaking treatment for patients in need.”